Company intelligence / Profile preview

Sofregen

Framingham, Massachusetts, United Statessofregen.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Sofregen has developed an advanced silk protein-based platform for soft tissue engineering. Its lead product, Silk Voice®, an injectable silk/hyaluronic acid implant, received FDA clearance in 2019 for vocal fold medialization and insufficiency. The company also markets the SERI® Surgical Scaffold (acquired in late 2016), cleared by the FDA in 2013. Clinical results show immediate volume restoration with long-term support of new tissue generation. Additional pipeline products are under development targeting broader aesthetic and reconstructive applications.

Therapeutic areas: OtherDermatology
Modalities: BiologicDevice (injectable implant)Recombinant protein (silk fibroin-based biomaterial)
Industry: Biotech

Drug pipeline

2 assets

Silk Voice Injectable Implant

Commercial

Indications: Vocal fold medialization, Vocal fold insufficiency

1 more asset in the full pipeline.

Request access →

Partnerships

Galderma – exclusive agreement to develop next-generation biostimulator fillers using silk technologyPENTAX Medical – exclusive distribution agreement for Silk Voice injectable

Beyond the preview

Go deeper on Sofregen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sofregen.

Explore the full profile